Glycomonitoring to monitor faster and better biotherapeutics.

Our Data

Glycosylation is a critical quality attribute of biologics. Assessment of glycosylation is key to maintain quality attributes as it impacts product lifespan, immunogenicity and efficacy. Glycosylation  is a non-template driven and highly process-specific modification that may lead to numerous combinations of heterogeneous glycans when cell cultivation modes are not robust enough. Therefore, Go /no Go decisions are to be made quite early in bioprocessing, especially to validate workflows and maximize productivity. There is a crucial need of advanced methods that assess glycan heterogeneity at all steps.

Eventhough a fully elucidated glycopattern of biologics is required by regulators, glycosylation cannot easily be traced online nor really controlled because glycan heterogeneity is highly versatile. No data are readily available online and as a result, product glycosylation is  often assessed post-production, found to be truncated and product efficacy is reduced. Expensive losses can be encountered as well. Product glycoprofiles do not need to be fully characterized throughout bioprocesses but rather, they need to be rapidly monitored to maximize efficacy and reproducibility  of cell line management and production.

To speed up a better and more efficient quality control, we have developed  a fast track glycomonitoring which can  provide the missing analytics daily, accelerate  and optimize the desired glycosylation to the highest titer at each step of biomanufacturing.

OD 450nM

OD 450nM

OD 450nM


Changing protein scaffold impact glycan structure

Glycosylation is a challenging quality attribute to meet regulatory compliance.

New generations of antibodies with non natural scaffold are being developed and may be difficult to express proteins.
IgG type scaffold largely impact glycoprofiles:

  • Wild-type IgG1: purple
  • Mutated IgG1: pink
  • Fc-fusion protein: red
  • Blank: blue

Glycoprofiles reflect the action of the cellular machinery on the product:
antibodies are known to display high content in fucose and variable content in galactose, thereby altering antibody cytotoxicity.


Viral capsids can display glycans

Viral vectors used for gene therapies are produced in cell lines that may widely vary upon process intensification:
There is a current need for advanced methods to assess process quality throughout the production, especially upscaling.

Glycoprofiling helps identify alteration of the capsid intactness during batch production

Primary Cells

Glycoprofiles are reproducible among donors

Cell therapies become increasingly developed and assessing quality of cell preparations is challenging. Gaining in productivity with adherent cells requests innovative methods to control cell expansion and upscaling.

Cell surface glycans can be used as a marker of robustness during cell isolation and expansion. A reference protein can be used  as a twin stanard to ensure the reproducibilty of the cultivation modes.
Assays can be also designed to define and assess cell differentiation wherever necessary.